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Multidrug-resistant tuberculosis (MDR-TB) is a significant health problem in Panama. The extent to which such cases are the
result of primary or acquired resistance and the strain families involved are unknown.We performed whole-genome sequencing
of a collection of 66 clinical MDR isolates, along with 31 drug-susceptible isolates, that were isolated in Panama between 2001
and 2010; 78% of theMDR isolates belong to the Latin American-Mediterranean (LAM) family. Drug resistance mutations corre-
lated well with drug susceptibility profiles. To determine the relationships among these strains and to better understand the ac-
quisition of resistance mutations, a phylogenetic tree was constructed based on a genome-wide single-nucleotide polymorphism
analysis. The phylogenetic tree shows that the isolates are highly clustered, with a single strain (LAM9-c1) accounting for nearly
one-half of the MDR isolates (29/66 isolates). The LAM9-c1 strain was most prevalent amongmale patients of working age and
was associated with highmortality rates. Members of this cluster all share identical mutations conferring resistance to isoniazid
(KatG S315Tmutation), rifampin (RpoB S531Lmutation), and streptomycin (rrs C517Tmutation). This evidence of primary
resistance supports a model in whichMDR-TB in Panama is driven by clonal expansion and ongoing transmission of several
strains in the LAM family, including the highly successful MDR strain LAM9-c1. The phylogenetic analysis also shows that the
LAM9-c1 strain is closely related to the KwaZulu-Natal (KZN) extensively drug-resistant TB strain identified in KwaZulu-Natal,
South Africa. The LAM9-c1 and KZN strains likely arose from a recent common ancestor that was transmitted between Panama
and South Africa and had the capacity to tolerate an accumulation of multiple resistance mutations.
Outbreaks of drug-resistant tuberculosis (TB) in various re-gions around the world have been increasingly reported (1).
Multidrug resistance (MDR), i.e., resistance to at least isoniazid
(INH) and rifampin (RIF), is estimated to have a frequency of
around 5% among TB cases globally. Extensively drug-resistant
(XDR) strains, i.e., resistant to INH, RIF, fluoroquinolones, and
one of three injectable second-line drugs (amikacin, kanamycin,
or capreomycin), have been observed in South Africa, Russia,
Eastern Europe, and East Asia (2–4). Multidrug resistance has
been associated with strains belonging to nearly everyMycobacte-
rium tuberculosis lineage (or strain family), including Beijing (5–
8), Latin American-Mediterranean (LAM) (9), and Central Asian
(CAS) (10, 11). In all cases investigated so far, multidrug resis-
tance inM. tuberculosis appears to result from stepwise acquisition
of mutations in individual resistance genes.
An open question is whether multidrug resistance spreads
through primary resistance or is acquired in the patient. In some
regions, there is evidence that drug resistance spreads by clonal
expansion and transmission of a single strain with multiple resis-
tance mutations (12, 13). In other regions, it appears that resis-
tance mutations arose multiple times independently, suggesting
repeated selection for resistance rather than transmission of a
well-defined MDR clone (14, 15). Either model can have signifi-
cant implications for local TB control policies. The success of an
MDR-TB strainmight require adaptivemutations that enable it to
tolerate the presumed fitness cost associated with multiple resis-
tance mutations. Although a subset of MDR strains appears to
have putative compensatorymutations in RpoC (16), a systematic
explanation for tolerance of resistance mutations in most other
MDR-TB strains is currently lacking.
Epidemiological surveys of TB strain families and drug resis-
tance in several Latin American countries, including Peru, Brazil,
Trinidad and Tobago, French Guiana, Paraguay, and Venezuela
(17–23), have shown that the LAM strain family predominates,
accounting for around 50% of the cases throughout this region
(24). Among Central American countries, the frequency of the
LAM strain family was found to be 55% inHonduras (25), though
the strain family appears to be less prevalent in Mexico (14.4%)
(26). The overall prevalence of MDR-TB cases in Panama is un-
known, since Panama has not conducted a national survey of an-
tituberculosis drug resistance to date. Since 2001, 93 cases of
MDR-TB have been reported to the PanamaNational Tuberculo-
sis Program, and a majority of those strains have been isolated,
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characterized, and archived through the Mycobacteriology De-
partment of the Laboratorio Central de Referencia de Salud
Pública in Panama. The extent to which MDR-TB in Panama is
driven by primary versus acquired resistance is currently un-
known.
In this article, we report the analysis of 66 MDR-TB clinical
isolates from Panama collected between 2001 and 2011 (approx-
imately two-thirds of the reported cases). A majority of the MDR
strains belong to the LAM TB strain family. Genome-wide single-
nucleotide polymorphism (SNP) analysis was used to construct a
phylogenetic tree in order to elucidate the relationships among the
isolates. The phylogenetic analysis showed that nearly one-half of
the MDR isolates (29 of 66 isolates) represent variants of a single
MDR strain, LAM9-c1, with a distinct combination of mutations
for resistance to isoniazid, rifampin, and streptomycin (STR),
suggesting on-going transmission (primary resistance) in this re-
gion. Nonetheless, individual members of this phylogenetic clus-
ter are continuing to acquire additional mutations for resistance
to other drugs.We show that this LAM9-c1 strain is closely related
to theKwaZulu-Natal (KZN) strain responsible for an outbreak of
XDR TB in South Africa.
MATERIALS AND METHODS
M. tuberculosis isolates. A set of 97 M. tuberculosis clinical isolates was
obtained from theMycobacteriologyDepartment of the LaboratorioCen-
tral de Referencia de Salud Pública in Panama. These isolates consisted of
66MDR-TB strains, whichwere coresistant to isoniazid (INH) and rifam-
pin (RIF), complemented by a sample of 31 drug-susceptible strains from
2009 and 2010. All isolates were tested using the standard proportion
method except for PanR1101, whichwas classified asMDRbased on a lack
of clinical response. Isolates were also tested for sensitivity to streptomy-
cin (STR) and ethambutol (EMB).
Characterization and drug susceptibility testing. Sputum samples
were first decontaminated using a modified version of the methodology
described by Petroff (27), according to the specifications of the PanAmer-
ican Health Organization. The presumptive M. tuberculosis isolates were
then characterized by biochemical assays, including the nitrate reduction
test, niacin production test, and catalase inhibition assay performed at
68°C (28). Finally, drug susceptibility testing was done with the Canetti
multiple-proportions method, using Lowenstein-Jensen (solid culture)
medium and the following antibiotic concentrations: 0.2 g/ml INH, 40
g/ml RIF, 4 g/ml streptomycin, and 2 g/ml ethambutol. Identifica-
tion of the isolates asM. tuberculosiswas confirmed using the commercial
AccuProbe hybridization assay (Gen-Probe), which has99% sensitivity
and specificity for theM. tuberculosis complex.
Whole-genome sequencing. The genome of each isolate was se-
quenced using an Illumina Genome Analyzer IIx, as previously described
(14). The samples were sequenced in paired-endmode, with a length of 36
to 54 bp for each read. Sequences were assembled by mapping reads to
H37Rv (GenBank accession number NC_000962.2) as a reference ge-
nome. Genome sequences for all 66 MDR strains were deposited in
GenBank. The sequencing datawere used to determine the spoligotypes of
the isolates by matching reads to the sequences of the spacers in the direct
repeats region (29) and matching them to the SpolDB4 database (24).
Phylogenetic analysis. A phylogenetic tree was constructed based on
genome-wide SNP analysis using maximum parsimony (PHYLIP v. 3.66,
provided by J. Felsenstein). A multisequence alignment was constructed
from the genomes of the 97 isolates, along with the genome sequences for
several published reference strains for comparison.We identified a total of
6,890 polymorphic sites at which wewere confident that at least one of the
strains was different from the others (where depth of coverage was at least
25% of the mean, and the majority nucleotide observed was represented
in 70% of the reads; gaps and regions with clusters of SNPs were ex-
cluded).
Epidemiological analysis. Epidemiological data for patients and na-
tional statistics were provided by the National TB Program in Panama,
which is coordinated by Cecilia Arango and Clara Torres. Due to the
retrospective nature of the study, the ability to conduct detailed tracing of
contact relationships and transmission dynamics was limited.
Nucleotide sequence accession numbers.Thegenome sequences of the
66 MDR isolates have been deposited in GenBank. Accession numbers are as
follows: PanR0201, ANZG00000000; PanR0202, ATAS00000000; PanR0203,
ATML00000000; PanR0205, ATMM00000000; PanR0206, ATMN00000000;
PanR0207, ATMQ00000000; PanR0208, ATMO00000000; PanR0209,
ATMP00000000; PanR0301, ATET00000000; PanR0304, ATES00000000;
PanR0305, ATER00000000; PanR0306, ATEQ00000000; PanR0307,
ATEP00000000; PanR0308, ATEO00000000; PanR0309, ATEN00000000;
PanR0311, ATEM00000000; PanR0313, ATEL00000000; PanR0314,
ATEK00000000; PanR0315, ATEJ00000000; PanR0316, ATEI00000000;
PanR0317, ATEH00000000; PanR0401, ATEG00000000; PanR0402,
ATEF00000000; PanR0403, ATEE00000000; PanR0404, ATED00000000;
PanR0405, ATEC00000000; PanR0407, ATEB00000000; PanR0409,
ATEA00000000; PanR0410, ATDZ00000000; PanR0411, ATDY00000000;
PanR0412, ATDX00000000; PanR0501, ATRP00000000; PanR0503,
ATRQ00000000; PanR0505, ATRR00000000; PanR0601, ATRS00000000;
PanR0602, ATRT00000000; PanR0603, ATRU00000000; PanR0604,
ATRV00000000; PanR0605, ATRW00000000; PanR0606, ATRX00000000;
PanR0607, ATRY00000000; PanR0609, ATRZ00000000; PanR0610,
ATSA00000000; PanR0611, ATSB00000000; PanR0702, ATSC00000000;
PanR0703, ATSD00000000; PanR0704, ANNN00000000; PanR0707,
ATSE00000000; PanR0708, ATSF00000000; PanR0801, ATSG00000000;
PanR0802, ANZH00000000; PanR0803, ATSH00000000; PanR0804,
ATSI00000000; PanR0805, ATSJ00000000; PanR0902, ATSK00000000;
PanR0903, ATSL00000000; PanR0904, ATSM00000000; PanR0906,
ATSN00000000; PanR0907, ATSO00000000; PanR0908, ATSP00000000;
PanR0909, ATSQ00000000; PanR1005, ANZI00000000; PanR1006,
ATST00000000; PanR1007, ATSR00000000; PanR1101, ATSS00000000.
RESULTS
Characteristics of patients and isolates. A total of 97 isolates
from TB patients in Panama were selected for phenotypic and
genotypic analyses, including 66 MDR isolates and 31 drug-sus-
ceptible isolates selected for comparison (Table 1). All 66 MDR
isolates were resistant to INH and RIF, and 47 (71%) were also
resistant to streptomycin. The samples were obtained from pa-
tients in several health regions in Panama, including Colón,
Panamá Metro, Chiriquí, Comarca Ngobe Buglé, San Miguelito,
Bocas del Toro, PanameEste, PanamáOeste, Veraguas, andCoclé.
The sample included twice as many male patients as female pa-
tients, ranging in age from 14 to 81 years. Nearly all of the cases
presented as pulmonary infections. Unlike in other regions where
HIV coinfection is endemic (such as sub-Saharan Africa), most of
the patients in this region were HIV negative (75% [39 of 52 pa-
tients tested]), and thus HIV coinfection is not implicated as a
major factor associated with MDR-TB in this region.
A majority of the isolates in the sample (57/97 isolates [58%])
belong to the LAM family. However, several otherM. tuberculosis
strain families were observed at lower frequencies (Table 1), in-
cluding members of the X clade (5%), T clade (16%), and H clade
(13%). Five isolates were labeled principle genetic group 1 (PGG-
1), because their spoligotypesmatched Beijing (2 isolates), CAS (1
isolate), and Manu (2 isolates), diverse members of this ancestral
lineage.While LAM strains are prevalent in Latin American coun-
tries (20, 24), the LAM family is particularly highly represented
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among the drug-resistant Panamanian isolates; 78.8% of the
drug-resistant strains (52/66 strains) are LAM.
The genome sequences of all 97 isolates were determined using
next-generationsequencing.Depthofcoverageandother sequencing
statistics are presented in Table S1 in the supplementalmaterial. Sin-
gle-nucleotide polymorphisms (SNPs) and insertions/deletions be-
tween isolates were determined usingmultisequence alignment. The
locations of the IS6110 transposon insertions were also identified.
The number of copies of IS6110 in the genome of each isolate ranged
between 1 and 16. There are two IS6110 insertions that appear to be
common among all of the LAM strains but are not found in isolates
fromother strain families.Oneof these occurs inRv3113, a phospha-
tase that is thought to be essential in vitro (30) and in vivo (31). Inter-
estingly, the insertion in Rv3113 in 7 of the isolates is 2 nucleotides
away from the position in the rest of the LAM isolates, implying that
this insertion event occurred at least twice.
To gain insight into the population structure of these isolates, a
phylogenetic tree was constructed for theMDR isolates based on a
genome-wide set of 6,890 SNPs (Fig. 1). Several published refer-
ence strains (H37Rv, CDC1551, F11, HN878, and KZN_4207)
were included in the phylogenetic analysis for comparison, and
Mycobacterium bovis BCG was used as an out-group. In this phy-
logenetic tree, isolates were clustered in several families, which
coincided with their grouping by spoligotype (see Table S1 in the
supplemental material). The clusters can be identified broadly
with strain families by spoligotypematching andmore specifically
by their association with known reference strains. The KZN_4207
and F11 strains clustered with the two largest LAM clusters,
CDC1551 with isolates of the X clade, H37Rv with the T clade
members, and the HN878 Beijing strain with the cluster repre-
senting PGG-1. For reference, a similar phylogenetic tree of the
drug-susceptible isolates is provided in Fig. S1 in the supplemental
material, showing that most of those isolates clustered with non-
LAM clades (clades T, H, and X and PGG-1).
The MDR strains in the LAM family were found to be subdi-
vided into four clusters. Members of the largest well-defined clus-
ter (called c1 or LAM9-c1) have the LAM9 spoligotype
(777777607760771) or a variant thereof, accounting for nearly
one-half (29 isolates) of the drug-resistant strains in the sample.
Cluster c2 (9 isolates) also has the LAM9 spoligotype, but mem-
bers of this cluster are not resistant to streptomycin (see below).
Cluster c3 (7 isolates) has the LAM3 spoligotype and is associated
with the F11 reference strain. Cluster c4 is associated with the
RDRio strain that was identified as a major cause of tuberculosis in
Brazil, because the isolates in this cluster all have the characteristic
26-kb deletion of Rv3347 to Rv3354 (32). They also have the
3,649-bp deletion of Rv1992 toRv1997 described for strainUT205
isolated from Colombia (33), suggesting a common origin for
these strains. However, the RDRio strain is probably not frequent
in Panama, because cluster c4 accounts for only 6% of the drug-
resistant isolates in our sample.
Drug resistance patterns among MDR strains. Drug resis-
tance patterns among the MDR strains are consistent with muta-
tions in individual genes associated with resistance to each drug
(Table 2). The overall frequency of INH and RIF resistance muta-
tions in this sample was described previously (34). The two most
prevalent mutations for INH resistance observed among the 66
MDR isolates were the S315Tmutation in KatG (70%, conferring
high-level resistance) and the C15T mutation in the inhA pro-
moter (20%, conferring lower-level resistance but also ethio-
TABLE 1 Summary of isolates sequenced
Characteristic Drug-resistant Drug-susceptiblea
Total no. of isolates 66 31
No. (%) of isolates with
resistance to:
INF plus RIF 66 (100) 0
STR 48 (73) 0
EMB 22 (33) 0
No. of cases by health region
Colón 23 4
Panamá Metro 21 27
Chiriquí 8 0
Comarca Ngobe Buglé 3 0
San Miguelito 4 0
Bocas del Toro 2 0
Panamá Oeste 2 0
Other (Paname Este, Veraguas,
and Coclé)
3 0
No. (%) of patients by gender
Male 44 (67) 26 (84)
Female 22 (33) 5 (16)
No. of patients by age (yr)
0–14 1 1
15–24 11 0
25–34 21 4
35–44 13 2
45–54 6 1
55–64 7 0
65 2 1
No data 5 22
No. (%) of isolates by strain
family
LAM 52 (78.8) 5
PGG-1 2 (3.0) 3
T clade 4 (6.0) 12
H clade 5 (7.6) 8
X clade 3 (4.5) 2
East African-Indian 0 1
No. (%) of patients by
tuberculosis type
Pulmonary 64 (97) NA
Extrapulmonary 2 (3) NA
No. of patients by treatment
outcome
Cured 22 NA
Died 28 NA
Default 7 NA
In treatment 5 NA
Untreated 1 NA
No data available 4 NA
No. of patients by HIV status
Seropositive 12 NA
Seronegative 39 NA
Not tested 15 NA
a NA, not available.
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namide coresistance) (34). As noted previously (34), mutations at
alternative (non-S315) residues in KatG appear to explainmost of
the remaining INH-resistant strains (8 of 10 strains) (see Table S2
in the supplemental material), as almost no mutations were ob-
served in other genes associated with INH resistance (35, 36). The
inhA promotermutation was associated primarily with non-LAM
MDR strains (8 of 14 isolates), whereas 50 of 52 LAMMDR strains
had some nonsynonymousmutations in KatG (and only 3 had the
inhA C15T mutation). Thus, INH resistance in the LAM strain
family is highly associated with mutations in KatG.
As previously reported (34), all but one of the resistant strains
had mutations in the RIF resistance-determining region of RpoB,
which is commonly seen in other RIF-resistant strains (37). Most
of the streptomycin-resistant strains had the nucleotide substitu-
FIG 1 Phylogenetic tree of the MDR isolates based on genome-wide SNP analysis (6,890 sites) with maximum parsimony. Branch lengths are proportional to
the number of nucleotide differences. The clusters in boxes are identified with strain families based on spoligotype.
Lanzas et al.
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tion C517T (30 isolates) or A514C (1 isolate) in rrs (the 16S
rRNA), 5 isolates had K43R or K88R mutations in RpsL, and 11
isolates had nonsynonymous or frameshift mutations in GidB
(38–40) (see Table S1 in the supplemental material). Although
resistance to pyrazinamide (PZA) was not evaluated in this sam-
ple, multiple strains (36 isolates) exhibitedmutations in pncA and
none of the drug-susceptible strains did, suggesting frequent PZA
coresistance (41). Strikingly, the mutations in PncA did not cor-
relate with specific clusters but consisted of 15 distinct mutations
scattered among individuals or small groups of isolates through-
out the phylogenetic tree (see Table S1 in the supplemental mate-
rial). This suggests that progenitors of the four LAMMDRclusters
were not PZA resistant but many individuals within those clusters
acquired PZA resistance independently. The gyrA locus (DNA gy-
rase) was examined for polymorphisms, and only 6 strains had
mutations associated with fluoroquinolone resistance (four had
the A90Vmutation and two had the D94Gmutation). Thus, most
of these MDR strains should retain fluoroquinolone sensitivity,
though this was not confirmed experimentally.
Certain resistance mutations were associated with clusters of
isolates (Table 3), suggesting that they were inherited from a com-
mon ancestor (cluster progenitors). This clustering explains the
prevalence of certain mutations in this sample. For example, the
prevalence of S531L in this population (78%) can be explained by
6 independentmutational events, two of whichwere subsequently
inherited by large clusters (c1, 29 isolates; c2, 9 isolates). Both
clusters c1 and c2 have well-defined resistance genotypes (all
members have KatG S315T and RpoB S531L mutations) and, in
addition, all c1 isolates have the rrsC517Tmutation. All members
of cluster c3 have the H526D mutation in RpoB. Although all
members of clusters c3 and c4were INH resistant, several different
INH resistance mutations were observed in these clusters.
It was recently proposed that mutations in RpoA and RpoC
could act as compensatory mutations for the fitness cost of RIF
resistance mutations in RpoB (16). To test this hypothesis, we
examined the sequences of RpoA and RpoC in the MDR isolates.
None of the isolates had any nonsynonymous mutations in RpoA
except for PanR0606 (with the RpoA mutation G31S). Further-
more, only one-quarter of theMDR strains (15 of 66 isolates) had
a nonsynonymousmutation in RpoC in the region around amino
acids 431 to 527 (Table 4). Strain PanR0304 had the RpoC muta-
tion V483G and strain PanR0909 had the RpoCmutation L527V,
both of which were previously reported for other RIF-resistant
strains (16). The other mutations in RpoC were not previously
reported and cover a total of 8 separate sites. Based on the phylo-
genetic analysis, the mutations were generally acquired subse-
quent to acquisition of RIF resistance mutations.
Identificationof amajorMDRcluster in theLAMfamily.The
LAM9-c1 cluster accounted for nearly one-half (29/66 isolates) of
the MDR isolates in this sample. Strains in this cluster had the
LAM9 spoligotype (777777607760771) or a variant thereof.
Strains in this cluster were uniformly resistant to INH, RIF, and
streptomycin. The LAM9-c1 cluster represents a distinct MDR
strain that has persisted in the population and has predominated
in the cases of MDR-TB in the Panama region over the past de-
cade. The dates on which these 29 isolates were obtained spanned
nearly the whole time period of the study (2002 to 2010). Isolates
of the LAM9-c1 cluster were found most abundantly in Colón
(66%) and Panamá Metro (21%) but also were represented as
isolated cases in nearly all of the geographic regions from which
samples were obtained (Fig. 2). This MDR strain was prevalent
among individuals of productive (working) age (15 to 64 years)
and was preferentially associated with male patients35 years of
age (odds ratio, 9.28; statistically significant by Fisher’s exact test,
P 0.044) (Fig. 3). Over one-half of the patients infectedwith this
strain died (15/29 patients [52%]), and this outcome was more
TABLE 2 Summary of the most-frequent mutations associated with
resistance to INH, RIF, and streptomycina
Drug Mutation No. of isolates
Isoniazid KatG S315T/G 47
InhA C15T 13
Other 11
Total 66b
Rifampin RpoB S531L 52
RpoB H526D/Y 9
RpoB D516F/V 4
Other 1
Total 66
Streptomycin rrs C517T 30
rrs A514C 1
RpsL K43R 4
RpsL K88R 1
Other 11
Total 47
a The conventional Escherichia coli numbering system is used for mutation positions in
RpoB and rrs.
b There was some overlap in isoniazid resistance mutations.
TABLE 3 Drug resistance polymorphisms associated with clusters in the
phylogenetic tree
Cluster
Total no.
of strains
Polymorphism (no. of strains/total no.)
InhA or KatG RpoB rrs
LAM9-c1 29 S315T (29/29) S531L (29/29) C517T (29/29)
LAM-c2 9 S315T (9/9) S531L (9/9) Nonea
LAM-c3 7 Variable (7/7) H526D (7/7) None
LAM-c4 4 Variable (4/4) Variable (4/4) None
a One of 9 LAM-c2 strains had the rrsmutation A514C.
TABLE 4 Nonsynonymous mutations in RpoC in the region around
amino acid 500 (amino acids 431 to 527), previously implicated to
possibly compensate for RpoB mutations
Strain(s)a Gene
Nonsynonymous
mutation
Lineage
(cluster)
0316 rpoC Val431Met X
0301 rpoC Gly433Ser X
0902 rpoC Val483Ala H
0304 rpoC Val483Gly LAM (c2)
0303 rpoC Val486Glu H
0203 rpoC Ile491Thr LAM (none)
0402 rpoC Gly519Val LAM (noneb)
0909, 0207, 0314, 0607, 0609,
0803, 0904, 0601
rpoC Leu527Val LAM (c1c)
a These are all MDR strains. No mutations were found in this region of RpoB in any of
the drug-susceptible strains.
b Associated with KZN strains.
c A subcluster (single branch) consisting of 8 of 29 isolates in the LAM9-c1 cluster.
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frequent than for any other strain cluster, although the difference
was not statistically significant, compared to the overall frequency
of death among MDR cases, which was 44% (2 0.77, df 1, P
 0.38).
The LAM9-c1 cluster can be distinguished from the other clus-
ters in the LAM clade by a specific combination of resistance mu-
tations, i.e., the KatG S315T, RpoB S531L, and rrs C517T muta-
tions (Table 3). The S315T mutation in KatG provides high-level
resistance to INH (42), and the S531L mutation in RpoB is the
most frequently observedmutation for RIF resistance among clin-
ical isolates (43). While each of these mutations is observed indi-
vidually with high frequency in monoresistant strains, only one
other MDR strain in the sample has exactly this combination of
resistance mutations. The fact that all members of the LAM9-c1
cluster share this combination of three mutations is consistent
with clonal expansion of a single drug-resistant strain. The long
branch for this cluster in the dendrogram (Fig. 1) is defined by a
set of 100 shared polymorphic sites found to be uniquely associ-
ated with LAM9-c1 isolates (see Table S3 in the supplemental
material). These could be used as genetic markers in future epide-
miological studies and/or could define unique phenotypic fea-
tures of this strain.
The KZN_4207 reference strain is associated closely with the
LAM9-c1 cluster in the dendrogram, implying that the Panama-
nian LAM9-c1 MDR strain is a variant of the KZN MDR/XDR
strains identified in KwaZulu-Natal, South Africa (9, 12, 44). The
KZN strains are in the LAM4 family and have a spoligotype very
similar to that of LAM9. The genomic data support the relation-
ship between these two strains. For example, both the KZN strains
and the LAM9-c1 strains have a 2,606-bp deletion encompassing
Rv0376 to Rv0378; the LAM-c2, LAM-c3, and LAM-c4 clusters do
not have this deletion. However, it is important to note that the
resistance mutations in the KZN MDR strain (strain V2475) and
XDR strain (strain R506) are different from those observed in
LAM9-c1. For example, V2475 and R506 have a deletion in gidB
that explains resistance to streptomycin, instead of theC517Tmu-
tation in rrs as in LAM9-c1, and V2475 and R506 both have mu-
tations in RpoB at amino acids other than S531. Both the
LAM9-c1 and KZN strains have distinct sets of unique SNPs
(shared among members of each cluster but not the other), so it
cannot be said that LAM9-c1 evolved from KZN or vice versa.
Nonetheless, the LAM9-c1 andKZN strains share a close common
ancestor in the LAM family and have both developed multidrug
resistance. However, none of the unique or shared SNPs in V2475
and R506 described previously (12) coincides with any of the 100
polymorphisms unique to the LAM9-c1 cluster (listed in Table S3
in the supplemental material), and a common polymorphism ex-
clusively associated with drug-resistant strains has yet to be iden-
tified.
DISCUSSION
Phylogenetic analysis of this sample of 66 drug-resistant strains
from Panama revealed that nearly one-half of the cases of
MDR-TB over the past decade have been caused by a single circu-
lating strain, LAM9-c1. The LAM9-c1 strain is a member of the
LAM strain family, which is prevalent in South andCentral Amer-
ica. The LAM9-c1 strain was identified in multiple health regions
within Panama, primarily among men 25 to 64 years of age. The
gender bias, which frequently is observed among TB cases, prob-
ably reflects sociocultural differences, in that men are more likely
than women to work and interact with wider networks of people.
While there is no direct evidence that LAM9-c1 is more virulent
than other strains ofM. tuberculosis, it is notable that over one-half
(52%) of the patients infected with this strain ultimately died. The
LAM9-c1 strain bears the resistance markers RpoB(S531L),
KatG(S315T), and rrs(C517T), conferring resistance to INH, RIF,
and streptomycin, respectively. Each of these mutations individ-
ually has among the lowest (but nonzero) fitness cost for each
drug (36, 45, 46). Putative compensatorymutations in RpoCwere
found in only a fraction of the MDR isolates; therefore, a general
molecular explanation for why these strains can tolerate the bur-
den of resistance mutations remains unknown.
Among the LAM strains as a whole, we observed that INH
resistance was almost exclusively associated with KatG mutations
rather than inhA promotermutations, including nonsynonymous
and stop-codon mutations at sites other than S315. This associa-
tion of KatG mutations with the LAM strain family is supported
by previous findings (47) and possibly reflects lineage-specific re-
sistancemutation pressures (e.g., epistatic interactions).Many in-
dividual isolates also had additional mutations in EmbB and
PncA, associatedwith resistance to ethambutol andpyrazinamide,
respectively. These latter mutations were more variable within
clusters and likely result from the use of these drugs in combina-
tion therapy. Fortunately, few of theMDR isolates have resistance
mutations in gyrA, suggesting that treatment with fluoroquinolo-
nes should still be clinically effective in this region.
Analysis of thegenomicdata shows that theLAM9-c1MDRstrain
in Panama is highly related to the MDR/XDR strain in KwaZulu-
Natal, South Africa (9). The phylogenetic analysis suggests that
both the LAM9-c1 and KZN strains evolved from a common pro-
FIG 2 Geographic distribution of LAM9-c1 cases. Numbers in parentheses
indicate the numbers of cases.
FIG 3 Association of the LAM9-c1 MDR strain with gender and age groups.
Values shown on the x axis are numbers of cases.
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genitor in the LAM family that might have had the capacity to
develop drug resistance through some as-yet-unidentified com-
pensatory mechanism, which was probably transmitted between
South Africa and South America via international travel. Panama
is recognized as a global trade center and experienced a large
amount of immigration from Africa in the early part of the 20th
century, during construction of the Panama Canal. Subsequent to
the construction of the Panama Canal, the African population in
Panama was decimated by three diseases, i.e., tuberculosis, diabe-
tes, and cancer. The most recent migration of Africans to Panama
was in the 1990s, including many Somalis escaping civil conflict.
The genomic data do not establish the direction of transmission
(despite the overall direction of migration, travel in the reverse
direction also occurs). Because it is not the case that most of the
SNPs in the KZN strain are a subset of the SNPs in the LAM9-c1
isolates or vice versa, it does not appear that either strain evolved
directly from the other. Nonetheless, the two clusters of isolates
share SNPs that are not found in the other LAM strains (e.g., c2,
c3, and c4 clusters), suggesting they had a recent common ances-
tor. Unlike in South America, LAM strains are significantly less
abundant in South Africa and represent a smaller proportion (10
to 30%) of TB cases (24, 48). In a recent study of the population
structure of MDR-TB strains in KwaZulu-Natal (49), the LAM
spoligotype was identified in 32% of the isolates, but 80% of
those were of the LAM4 spoligotype (associated with KZN TB
strains) and the rest had the LAM3 spoligotype. In contrast, the
LAM9 spoligotype (associated with PanamaMDR cluster c1) was
not observed among 233MDR isolates in KwaZulu-Natal andwas
observed for only 0.7% of the isolates from the Eastern Cape and
theWestern Cape combined (49). Thus, it appears that the occur-
rence of the two strains is mostly region specific, with LAM9-c1 in
Panama and the KZN strain in KwaZulu-Natal (despite the fact
that isolated cases of transmission to other countries have been
reported [50]). However, it should be noted that some LAM9
MDR strains have been identified in other provinces near KZN,
including Gauteng and Mpumalanga (51).
The clonal nature of the MDR-TB cases in Panama suggests
that MDR-TB in this region is driven by ongoing transmission,
rather than by repeated acquisition of mutations in independent
hosts (which might result frommedical nonadherence, for exam-
ple). The significant clustering of isolates in the phylogenetic anal-
ysis provides strong evidence of primary resistance resulting from
transmission of one of a few circulating MDR strains, dominated
by LAM9-c1. Each cluster appears to have acquired a distinct sig-
nature of resistance mutations for the first-line drugs INH and
RIF, as well as streptomycin (for LAM9-c1). The origin of these
drug-resistant LAM strains could be due to the fact that directly
observed therapy was not widely adopted as a standardized treat-
ment regimen in Panama until around 2005. Some individual
isolates have continued to acquire additional resistancemutations
for other drugs such as pyrazinamide, reflecting the adaptability of
these strains. The apparent ability of these strains to tolerate an
accumulation of resistancemutations has likely contributed to the
maintenance of these MDR strains within the population of Pan-
ama over a decade.
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